Illumina DRAGEN GCP Lvl 4 1-year License

The National Institutes of Health (NIH) Office of Logistics and Acquisition Operations is preparing to procure a 12-month subscription to the Illumina DRAGEN GCP Level 4 platform on behalf of the National Institute of Neurological Disorders and Stroke (NINDS), with responses due by September 10, 2026, and an anticipated award date of September 30, 2026. This is a sole-source acquisition to Illumina, Inc., authorized under 41 U.S.C. 1901 and not subject to set-aside.

The platform will process approximately 1,300,000 GB of whole-genome sequencing data derived from 10,000 human genomes during the 12-month performance period (September 30, 2026, through September 29, 2027). The contractor must provide graph-based alignment to the human reference genome (hg38), variant calling with detection of single-nucleotide variants, insertions/deletions, structural variants, copy number variants, and repeat expansions. Full compatibility with Illumina-generated sequencing data and existing DRAGEN-processed datasets is required, along with continuous operational availability throughout performance.

Deliverables include platform access, aligned sequence files (CRAM format), and variant call outputs (VCF files) meeting DRAGEN quality standards. The contractor must comply with NIH, HHS, and NIST information security standards, prohibits use or disclosure of government-furnished genomic data, and restricts vendor publication using processed data. Deidentified genomic data must be protected as confidential throughout processing.

The anticipated award value is $113,004 ($11.30 per genome). The acquisition will be procured under FAR Part 12 Simplified Acquisition Procedures. Responses must be submitted to Contracting Officer Ijada Fields at ijada.fields@nih.gov, referencing presolicitation number 75N98026Q01035.